Cytoplasmic protein extracts from chronic myelogenous leukemia (CML) cells contained an activity that altered the electrophoretic mobility of complexes formed between nuclear proteins and the transcriptional enhancers of interferon (IFNI-inducible genes. Exposure of CML cells to IFN-a diminished the effect of the CML cytoplasmic proteins on these nuclear protein-DNA complexes. The pres-N CHRONIC myelogenous leukemia (CML), an underly-I ing defect in growth regulation related to the Philadelphia chromosome translocation leads to an accumulation of high numbers of myeloid cells. The chronic or benign phase lasts a median of 4 years, following which the acquisition of additional mutations leads to a more acute form of leukemia in which the patients die of bleeding and infection.'
Cytoplasmic protein extracts from chronic myelogenous leukemia (CML) cells contained an activity that altered the electrophoretic mobility of complexes formed between nuclear proteins and the transcriptional enhancers of interferon (IFNI-inducible genes. Exposure of CML cells to IFN-a diminished the effect of the CML cytoplasmic proteins on these nuclear protein-DNA complexes. The pres-N CHRONIC myelogenous leukemia (CML), an underly-I ing defect in growth regulation related to the Philadelphia chromosome translocation leads to an accumulation of high numbers of myeloid cells. The chronic or benign phase lasts a median of 4 years, following which the acquisition of additional mutations leads to a more acute form of leukemia in which the patients die of bleeding and infection. ' Alpha-interferon (IFN-a) induces complete hematologic remissions (all cells are Philadelphia chromosome-positive, but the differential count and white blood cell count are normal) in 70% of patients and a complete cytogenetic remission (all cells are diploid) in 15% of early phase CML patients.' Fifteen percent to 30% of early chronic phase CML patients show primary resistance to IFN-a at diagnosis. The mechanism through which IFN-a! mediates its clinical effect in CML and the reasons for these variable levels of sensitivity to IFN are unknown.
Alpha-interferon exerts its immunomodulatory and antiviral effects by activating the transcription of histocompatibility and antiviral genes. It also alters the transcriptional activity of several other genes commonly known as IFNinducible genes. This transcriptional activation is mediated through alteration of nuclear proteins that bind to the 5' transcription-regulatory regions of IFN-inducible genes before the activation of gene To test the hypothesis that the action of IFN-a in CML is also associated with changes in nuclear DNA-binding proteins, we isolated nuclear proteins from CML patients who were either clinically resistant or sensitive to IFN-a. We then studied the electrophoretic mobility of the complexes formed between these nuclear proteins and IFN-inducible transcriptional enhancers. The transcriptional enhancers used were taken from the 5' region of the IFN antiviral gene 2,5-oligoadenylate synthetase (2,5-OAS)?' the IF" immunomodulatory gene beta-2 microglobulin: and the IFNinducible genes 9-21' and 6-16; which are of unknown function. ' We found that the electrophoretic mobility of complexes between the IFN-inducible transcriptional enhancers and the nuclear proteins isolated from the unfractionated peripheral blood cells of CML and normal individuals were different before IFN exposure. The complexes formed by nuclear proteins isolated from unfractionated normal peripheral blood cells resembled those formed by nuclear proteins from unfractionated CML peripheral blood cells after the ence of clinical responsiveness to IFN-a correlated with the sensitivity to the IFN-induced change in the electrophoretic mobility of nuclear protein-DNA complexes. These data suggest that the action of IFN-a in CML may be linked to a pathway that can result in posttranslational modification of nuclear proteins. 0 1990 by The American Society of Hematology.
nuclear proteins from normal peripheral blood cells were exposed to a phosphatase-like activity found in cytoplasmic proteins of CML myeloid cells. Alpha-interferon treatment changed the electrophoretic mobility pattern of complexes formed by nuclear proteins of CML peripheral blood to that of normal peripheral blood cells. This IFN-induced change occurred in CML patients who were known to be clinically sensitive to IFN-a! but did not occur in CML patients who were clinically resistant to IFN-a.
MATERIALS AND METHODS
Patients were treated with daily subcutaneous injections of 5 to 10 x lo6 U of IFN-a. In vitro experiments involved the use of 1,000 U/mL of recombinant IFN-a at 37°C at pH 7.4 for 1 hour. The concentration used for in vitro experiments (1,000 U/mL) is four times the peak serum level usually seen 2 hours after a subcutaneous injection of 5 x lo6 U of recombinant IFN-a.
The peripheral blood samples used for this study were obtained as incidental samples from routine diagnostic or response evaluation procedures approved by the M.D. Anderson Surveillance Committee. Some of the samples from CML patients "off of IF"' (patient not receiving IFN at time sample was taken) were obtained at diagnosis before institution of therapy, while all of the samples from CML patients receiving IFN were obtained at variable time points after initiation of IFN therapy. The time after initiation of therapy at which these samples were obtained is indicated in Table 4 (see  Results) . This is primarily a retrospective study in that the majority of samples were obtained after the response status was known. (lanes 1 and 2); 6' regubtory region of the bcteriml alkaline pho8phetau gene (GAGACTTATAGTCGCTTL whkh is not homdogorn and does not compete (lanes 3 and 41: a 6' regulatory &e of the zeta globin gene ( TGTGGTCAGACTCTGGCCAACACCCCCTGTAAGGCCACA.
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Patients chosen for this study were those in whom the responsivemss to IFN could be determined from the clinical history.
Patients responding to a combination of l F N a and chemotherapy wen excluded from analysis in Table 4 as their sensitivity to l F N s as a single agent was inevaluable. The analysis and interpretation of the electrophoretic mobility analysis of nuclear protein DNA complexes were performed by individuals unfamiliar with the IFN response status.
Mohi/ity-shlff anu/ys/s. Nuclear proteins were isolated from peripheral blood cells or cell lines by the method of Mbkimens et all0 or by the method of Dignam et al." The mobility-shift assay was performed as dacribed by Tnisman." except that the binding buffer contained I20 mmol/L NaCI. IO mmol/L Tris. pH 7.5.20 mmol/L 2-mercaptoethanol. I mmol/L ethylenediamine tetraacetate. 4% glycerol, and 0.1% Triton X-100. All protein-binding assays were performed after the unfractionated nuclear proteins (2 to I2 rg) had been incubated with a final concentration of 0.1 mg/mL of poly (dl) poly (dC) for I5 minutes at 4%. The nuclear proteins were then exposed for I hour at 4% to 100 fmol or IO'cpm of the transcription enhancer oligonucleotide. which was "P end-labeled by the Klenow reaction. The nuclear protein-DNA annplcxes were electrophoresed in a 7.5% polyacrylamide gel at 5 V/cm for I2 hours in a Tris-acetate bufer. Quantitation of the high-and low-mobility complexes was made by scanning densitometry. Oligonucleotides wen synthesized in the M.D. Andmon oligonucleotide synthesis core laboratory and the sequence of the products verified by Malam-Gilbert sequencing reactions." nuclear cells w e n isolated lrom incidental samples obtained from routine platelet apheruis. Lymphocyte and monocyte populations were isolated by centrifugal elutriation. Mbnocyte fractions were shown to be over 95% monocytes by staining with alpha-naphthyl butyrate. The lymphocyte fraction was determined to be greater than 95% lymphocytes by Giemsa stain.
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RESULTS
Complexes formed berwnn inret$erott-inducible rramcrip rional enhancers and nuclear proreins from lymphoid or myeloid cells. We used the mobility-shift assay IO study For personal use only. on September 24, 2017. by guest www.bloodjournal.org From the electrophoretic mobility of complexes formed between nuclear proteins and IFN-inducible transcriptional enhancers. The nuclear proteins of normal monocytoid cells fractionated from normal peripheral blood cells form a high-mobility complex (Fig la) with the transcriptional enhancers of the IFN-inducible gene 2,5-OAS. The nuclear proteins from normal peripheral blood lymphoid cells form a low-mobility complex (Fig la) . The nuclear proteins isolated from lymphoid cell lines (Fig Ib) form a low-mobility complex with the 2,5-OAS IFN-inducible transcriptional enhancer, while the nuclear proteins of myeloid cell lines form a highmobility complex ( Fig Ib) .
The nuclear proteins of lymphoid and myeloid cells formed low-or high-mobility complexes, respectively, with the IFNinducible transcriptional enhancers (Table 1 ) of the beta-2 microglobulin and the 6-16, 9-27, and 2,5-OAS genes ( Fig  IC) . Nuclear proteins from monocytoid cell lines formed high-mobility complexes, whereas nuclear proteins from erythroid cells (HEL, K562,OCIM-2) formed low-mobility complexes. The mRNA levels of the 2,5-OAS, 6-16, and 9-27 genes have been shown to be IFN-inducible in myeloid as well as lymphoid cells in our own laboratory as well as in those of others.I4
Sequence specificity of nuclear protein binding assay. We incubated nuclear proteins from the HL60 cell line, which forms both the high-and low-mobility complex, with the 32P Klenow end-labeled 2,s-OAS 5' transcriptional enhancer oligonucleotide (Table 1; Fig 2, lane 21) in the presence or absence of unlabeled oligonucleotides that were homologous or nonhomologous to the "P-labeled 2,5-OAS oligonucleotide. When we added a 50-or 100-fold molar excess of a 2,S-OAS transcriptional enhancer oligonucleotide itself (Fig 2, lanes 17 and 18) , we observed almost complete inhibition of binding of nuclear proteins to the 32P-labeled oligonucleotide. Addition of a 50-fold excess of a region further 5' to the 2,5-OAS transcriptional enhancer (Fig 2,  lanes 19 and 20) , which contained regions homologous to the 32P-labeled 2,5-OAS transcriptional enhancer, also led to inhibition of binding. When we added a 50-or a 100-fold molar excess of unlabeled oligonucleotides that were not homologous (Fig 2, lanes 1 through 4 and 7 through 12), no reduction in the binding of nuclear proteins to the 32P-iabeled oligonucleotide occurred. Addition of oligonucleotides containing elements that exhibited homology to the 2,S-OAS transcriptional enhancer oligonucleotide showed inhibition of binding of the "P-labeled 2,S-OAS oligonucleotide (Fig 2, lanes 5, 6, and 13 through 20). These experiments demonstrate that the binding of nuclear proteins to DNA is sequence-specific under the conditions of our experiments.
Complexes formed between the interferon-inducible transcriptional enhancers and nuclear proteins extracted from chronic myelogenous leukemia and normal cells before interferon exposure are diflerent. Nuclear proteins extracted from the unfractionated normal peripheral blood cells of all 18 normal donors tested formed both a lowmobility complex and a high-mobility complex with the 2,5-OAS oligonucleotide (Table 2 ; Fig 3a) .
The nuclear proteins isolated from unfractionated peripheral blood cells of all 44 C M L patients tested (see patient data in Table 3 and lane 1 of Figs 3b and 3c) formed the high-mobility complex. The low-mobility complex was undetectable in 40 of the 44 untreated C M L samples tested (see Tables 2 and 3 and lane 1 of Figs 3b and 3c). The low-mobility complex was undetectable even when 20% of the peripheral blood cells were lymphoid (patients no. 6, 25, 32, and 36 in Table 3 ).
In vivo exposure to alpha-interferon alters the complexes formed between interferon-inducible transcriptional enhancers and nuclearproteins. We then studied the in vivo effect of IFN-a on the electrophoretic mobility of complexes formed between nuclear proteins isolated from the unfractionated peripheral blood cells of CML patients and IFNinducible transcriptional enhancers. The CML patients we studied exhibited the following different clinical response patterns to IFN-a, which indicate different levels of sensitivity to IFN-a: complete or partial hematologic remissions (Table 4) , partial cytogenetic remissions (Table 5) , complete cytogenetic remissions (Table 6 ), primary or de novo resistance defined as failure of IFN to decrease the white blood cell count to below 20,000/mm3 in 3 months of therapy (Table 7) , and secondary resistance (the loss of hematologic or cytogenetic remission) while receiving IFN-a ( Table 7) . The patients were usually treated 3 to 6 months before the response status was defined. Interferon antibodies were ruled out as a cause of clinical resistance in all resistant patients included in this study.
As shown in lane 2 of Fig 3b, when the nuclear proteins were extracted from the unfractionated peripheral blood cells of IFN-sensitive CML patients during IFN therapy, both low-and high-mobility complexes were detected in 10 of Table 2 . Interferon For personal use only. on September 24, 2017. by guest www.bloodjournal.org From Table 2 ). This result contrasts with the absence of the low-mobility complex when the nuclear protein is extracted from the unfractionated priphera1 blood cells of the same CML patients during a period when they were not being treated with IFN-u ( Tables 2 and 3 and lane I of Fig 3b) .
The nuclear proteins extracted from the unfractionated IFN-exposed peripheral blood cellsof CML partial (patients no. 7 and 54 through 64 in Table 5 ) or complete (patients no. 65 through 7 I in Table 6 ) cytogenetic remitters also formd the low-mobility complex with the transcriptional enhancers of IFN-inducible genes. This occurred in 18 of 19 cases tested: I I of I2 partial cytogenetic responders and seven of Seven complete cytogenetic responders ( Table 2) . Table 7 ). The difference between the numbers of IFNresistant and -sensitive CML patients whose unfractionated peripheral blood cells arc sensitive to the IF?J-induced effect on nuclear protein complexes is statistically significant (P -.01). This ditTercnce isshown in Table 2 .
In vitro effect of olpho-interferon on nuclear proteins thur bind to interJerowinducihle :ronscripriono/ mhomws. We exposed unfractionated peripheral blood cells. from a CML patient who exhibited IFN sensitivity at the time of the assay, in vitro. to 1.000 U/mL of IFN-u for I hour at 37OC. As shown by a comparison of the mobility-shift assay of the Abbreviations: Ph, Philadelphia chromosome; CHR, complete hematological remission; S, sensitivity; 1 O R , primary resistance; 2OR. secondary resistance; INE, inevaluable; WBC, white blood cell count; DOAP, daunomycin, oncovin, ara-C, and prednisone. *% Low-mobility complex, low-mobility complex (band A)/low (A)-and high (8)mobility complex x 100. as determined by scanning densitometry of autoradiographs of mobility-shift assays. These were performed to estimate the percent of the nuclear proteins bound to the IFN-inducible regulatory element which ere involved in the low-mobility complex versus the high-mobility complex.
?Patient no. 5 was Philadelphia chromosome negative at diagnosis, but positive for a chimeric bcr-ab1 gene by Southern analysis.
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From complexes formed by the nuclear proteins before (Fig 4a, lane 3) and after (Fig 4a, lane 4) in vitro exposure to IFN, this resulted in an increase in the intensity of the lowmobility complex (band A in lane 4 of Fig 4A) . The blood sample of the same IFN-sensitive C M L patient exposed in vivo to IFN-a (Fig 4a, lanes 1 and 2) No change in the electrophoretic mobility of nuclear protein-DNA complexes was seen when the cells of IFNresistant C M L patients were exposed in vitro to IFN before nuclear protein isolation (Fig 4b) .
The IFN-induced change in nuclear protein-DNA complex mobility, which was seen in cells of IFN-sensitive C M L patients, did not require de novo protein synthesis, as the addition of cycloheximide in vitro to the peripheral blood cells of a C M L patient before the cells were exposed to IFN did not prevent IFN-induced changes in nuclear protein complexes (Fig 4c, lane 3) .
Cytoplasmic protein of chronic myelogenous leukemia myeloid cells alters nuclear protein complexes. If lymphocytes were first purified from the myeloid cells present in C M L peripheral blood before cell lysis and nuclear protein isolation, a low-mobility complex was formed between the IFN-inducible transcriptional enhancers and the nuclear proteins of the lymphoid cells (Fig 5) . These data suggested that there was an activity in the peripheral blood myeloid cells of Philadelphia chromosome-positive C M L cells that was released a t the time of cell lysis and altered in vitro the nuclear proteins of lymphoid cells.
To directly test this hypothesis, we added a small amount of cytoplasmic protein of the peripheral blood myeloid cells of an IFN-sensitive C M L patient to the nuclear proteins of an established lymphoid cell line (Daudi). We have previously shown that the electrophoretic mobility of the complex formed between the IFN-inducible enhancer and the nuclear proteins of normal lymphoid cells or established lymphoid cell lines was identical. The addition of the C M L cytoplasmic protein caused a reduction in the intensity of the lowmobility complex and the formation of a more rapidly migrating complex (Fig 6a) . The mobility of this more rapidly migrating complex was similar to that of the complexes formed by nuclear proteins of C M L cells. Similar
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From changes occurred when the peripheral blood cells of an IFN-resistant CML patient were used to generate a cytoplasmic extract (Fig 6b) . However, almost no change was seen when the cytoplasmic proteins of the peripheral blood cells of a normal individual were used to generate the cytoplasmic extract or when the mature marrow cells (bands and neutrophils) of a normal individual were used to generate the cytoplasmic extracts (Fig 6c, lane 3) . The cytoplasmic proteins of the immature marrow myeloid cells (blasts and promyelocytes) generated only a small amount of change on the nuclear protein complexes (Fig 6c, lane 2) . These in vitro experiments were performed in the presence of high concentrations of the protease inhibitors phenylmethylsulfonyl fluoride, aprotinin, and benzamide. The change induced in the mobility of the nuclear protein complexes by the CML cell lysate was temperature (occurred a t 22OC, but not at 5OC) and time (barely detectable at 5 minutes, but complete by 1 hour) dependent. This activity was localized predominantly in the cytoplasm of C M L myeloid cells. The levels of this activity in the peripheral blood myeloid cells of normal individuals were almost undetectable, although it was present in blasts and promyelocytes isolated from the marrow of normal individuals. The addition of orthovanadate (0.01 to 0.1 mmol/L), Abbreviation: S, sensitivity. which is a phosphatase inhibitor." to CML cells before isolation of cytoplasmic proteins or to the cytoplasmic proteins themselves. diminished the effect of the cytoplasmic proteins on the electrophoretic mobility of nuclear protein complexes (data not shown). Finally, IFN treatment of the cells of IFN-sensitive patientsappred todiminish theeffect of the CML cytoplasmic protein on the electrophoretic mobility of these nuclear protein-DNA complexes (Fig 6a.   lane 5) .
Exposure of the cells of IFN-resistant CML patients to IFN-a. did not diminish the effect of the cytoplasmic protein on electrophoretic mobility of IFN-inducible complexes. as shown in lane 3 of Fig 6b. This data suggested that there was an activity in the peripheral blood myeloid cells of CML patients. which is not present in normal peripheral blood myeloid cells. that altered the electrophoretic mobility of complexes between transcriptional enhancers and nuclear proteins.
We then tested in vitro the effect of purified enzymes that might account for this effect of CML cellular proteins on nuclear proteins. When we added an acid phosphatase to the nuclear proteins from the Daudi cell line. the intensity of the low-mobility complex (lane I ) decreased and complexes of more rapid mobility (lanes 2and 3) wercgenerated.asshown in Fig 7. As shown by a comparison of lanes 2.3. and 4. the electrophoretic mobility of the acid phosphatase-treated nuclear proteins was higher than that formed by Daudi nuclear proteins before phosphatase exposure. Thus. the effect of acid phosphatase is to generate complexes that have mobilities similar to those Seen with nuclear proteins from normal lymphoid or Daudi cells following exposure to the cytoplasmic proteins of CML cells (Fig 6) . The electrophoretic mobility of the high-mobility complexes g~neratcd in lanes 2 and 3 by exposure to phosphatase is slightly less than that of the high-mobility complex present in the CML cell line EM-2 (Fig 7. lane 4) . This may reflect the d e g m to which the potato phosphatase can dephosphorylate the nuclear proteins of the Daudi cells in vitro. These data suggest that the cytoplasm of CML cells contains a phosphatase that alters the mobility of the complexes formed between nuclear proteins and IFN-inducible transcriptional enhancers. and that IFN-a reverses these changes through a posttranslational effect in the IFN-sensitive Philadelphia chromosomepositive CML myeloid cell.
DISCUSSION
Our studies show that the cytoplasmic proteins of CML peripheral blood myeloid cells induced a change in the electrophoretic mobility of complexes formed between the transcriptional enhancer sequences of the IFN-inducible genes 6-16.9-27. beta-2 microglobulin. and 2.5-0AS and the nuclear proteins of hematopoietic cells. The CML cytoplasmic proteins converted the electrophoretic mobility of nuclear protein-DNA complexes from low to high mobility. The cytoplasmic proteins of the mature myeloid peripheral blood cells of normal individuals had little or no effect on the mobility of these complexes. Thus. the presence of proteins (which alter nuclear protein-DNA complexes) in the cyto. plasm of CML cells may account for the differences Seen in the electrophoretic mobility of the complexes formed between transcriptional enhancers and the nuclear proteins of normal versus CML myeloid cells. Alpha-interferon appears to oppose this effect of CML cytoplasmic proteins on the electrophoretic mobility of nuclear protein-DNA complexes in cells of CML patients clinically sensitive to 1FN-u.
The sensitivity of cells to the IFN-induced changes of the electrophoretic mobility of nuclear protein-DNA complexes was observed in 10 of IO 1FN-u hematologic responders tested. in I 1 of I2 partial cytogenetic responden tested. and in seven of Seven of the complete cytogenetic responders tested. The complexes formed by the interferon-inducible transcriptional enhancer and the nuclear proteins of only one of the 13 IFN-a-resistant CML patients tested exhibited changes in electrophoretic mobility following IFN. This difference between the sensitivity to the IfN-u-induced effect on nuclear protein-DNA complexes in clinically sensitive (?? of 29) and resistant (one of 13) patients was statistically significant ( P c .Ol) ( Table 2) .
A correlation between in vitro sensitivity to the antiproliferativc effect of IFN and the sensitivity to the 1FN-ainduced changes in the binding of nuclear proteins has also recently been reported in IFN-sensitive and -resistant B cell lines.'' Our data suggest that the pathway through which IFN induces changes in the electrophoretic mobility of nuclear protein-DNA complexes may be playing a role in the binding of direrent nuclear proteins to the IFN-inducible transcriptional enhancer. The nuclear protein binding assay described in this rrpon may be useful in predicting the responsiveness of CML patients IO I l~N a therapy. We are conducting a prospective evaluation of this assay as a predictor of de novo sensitivity or mistance to IFN-a. Further studies will focus on the characterization of the structure of thac nuclear proteins and their posttranslational modifications. which occur in both normal individuals and CML patients after exposure to IF%.
